Psychiatric comorbidities in neurological practice present significant diagnostic hurdles, especially when severe psychotic manifestations arise alongside seizure disorders. Psychosis of epilepsy is a complex clinical condition encompassing several temporal and phenotypic subtypes. Historically, clinicians categorized these syndromes primarily by their timing relative to seizures, identifying interictal, postictal, and treatment-emergent psychoses. However, the exact genetic foundations and clinical differences distinguishing these subtypes have remained unclear. Recent landmark investigations have shed light on the phenotypic patterns and genotypic architecture of this challenging disorder. By combining comprehensive clinical phenotyping with advanced molecular diagnostics and polygenic risk analyses, researchers have uncovered critical distinctions. These findings demonstrate that rare high-penetrance genetic variants and shared common polygenic liabilities differentially govern specific psychotic presentations in epilepsy. Consequently, these insights offer clinicians a much clearer diagnostic and therapeutic framework.

Clinical Classification and Phenotypic Spectrum of Psychosis of Epilepsy

Phenotypic characterization reveals distinct subcategories within the spectrum of epilepsy-related psychiatric illness. In comprehensive cohort studies, interictal psychosis emerges as the most prevalent presentation, accounting for approximately 70% of identified cases. Among patients experiencing interictal manifestations, schizophrenia and schizophreniform disorders represent the single largest clinical subgroup. In contrast, postictal psychosis occurs in roughly 23% of affected individuals, typically developing within a brief period following a cluster of seizures. Furthermore, clinicians occasionally encounter medication-induced psychosis, representing around 2% of presentations, as well as substance-induced psychosis in nearly 5% of patients. Therefore, accurately establishing the chronological relationship between seizure activity and psychiatric symptoms remains fundamental. Clinicians must carefully differentiate acute, transient postictal confusion from persistent interictal delusions and hallucinations. Notably, recognizing these distinct clinical phenotypes allows neurologists and psychiatrists to tailor immediate pharmacotherapy and long-term surveillance appropriately.

Postictal Psychosis Versus Interictal Syndromes: Clinical Divergence

A critical finding involves the divergent neurobiological associations seen between focal and generalized epilepsies. Specifically, focal epilepsies exhibit a remarkably strong association with postictal psychosis, occurring in more than 85% of such cases. In comparison, focal epilepsy features in less than half of patients with interictal psychotic presentations. Furthermore, patients with postictal episodes frequently exhibit temporal lobe foci and experience a distinct lucid interval following seizure clusters before psychiatric decompensation occurs. In contrast, patients with interictal psychiatric disorders frequently manifest chronic psychotic symptoms regardless of recent seizure frequency. Consequently, this profound phenotypic divergence highlights different underlying pathophysiological mechanisms. Postictal episodes appear intimately linked to transient network exhaustion and dynamic neurochemical fluctuations following focal seizure discharges. Conversely, interictal presentations reflect more enduring structural, neurodevelopmental, and genomic vulnerabilities. Recognizing these differences prevents premature diagnoses of chronic schizophrenia in patients experiencing reversible postictal states.

Rare Pathogenic Variants and Monogenic Epilepsy Genes

Molecular genetic analysis has illuminated crucial biological drivers behind epilepsy-associated psychoses. Approximately 29% of patients with psychosis of epilepsy harbor rare pathogenic genetic variants or chromosomal anomalies. Notably, these variants predominantly reside in well-established epilepsy genes, including SCN1A, PCDH19, DEPDC5, KCNT1, CHD2, SLC2A1, NPRL3, CLN3, ATP1A3, and CACNA1A. Moreover, chromosomal structural variations contribute to a notable subset of cases. Interestingly, patients carrying rare pathogenic variants display a pronounced predisposition toward interictal schizophrenia or schizophreniform phenotypes rather than postictal episodes. Indeed, more than 55% of individuals with pathogenic monogenic variants present with interictal psychosis, whereas fewer than 10% present with postictal psychosis. Thus, monogenic disruptions in neuronal excitability, ion channels, and mammalian target of rapamycin signaling pathways may directly predispose individuals to both unprovoked seizures and chronic psychotic disorders. These findings strongly encourage early genetic evaluation in complex neuropsychiatric cases.

Polygenic Architecture and Schizophrenia Risk Scores

Beyond rare monogenic mutations, common polygenic variation plays a decisive role in specific psychiatric phenotypes. Researchers utilized genome-wide polygenic risk scores to evaluate common schizophrenia risk alleles in epilepsy cohorts. Consequently, they demonstrated that overall polygenic risk is significantly enriched in individuals with psychosis of epilepsy compared to general population controls. However, further stratification revealed that elevated polygenic risk scores associate specifically with interictal schizophrenia. In striking contrast, patients experiencing postictal psychosis or alternative interictal phenotypes do not display elevated schizophrenia polygenic risk scores. This critical discovery proves that interictal schizophrenia in epilepsy shares authentic genetic etiology with primary schizophrenia. Meanwhile, postictal psychosis arises from distinct seizure-driven network dynamics rather than polygenic psychiatric liability. Therefore, polygenic scoring provides compelling objective evidence that divergent genomic mechanisms drive separate clinical subtypes across the spectrum of seizure-related psychotic disorders.

Diagnostic and Neuropsychiatric Implications for Practice

These groundbreaking genetic and phenotypic insights carry direct implications for everyday clinical management. Clinicians managing refractory epilepsy must maintain heightened vigilance for psychiatric symptoms, especially in individuals harboring known pathogenic variants. When psychotic symptoms emerge, clinicians should promptly obtain detailed chronological histories regarding seizure occurrence, antiepileptic drug adjustments, and lucid intervals. Furthermore, identifying a monogenic etiology can optimize antiepileptic drug selection while avoiding agents that exacerbate psychiatric instability. For example, clinicians should exercise caution with medications like levetiracetam in patients with high psychiatric vulnerability. Similarly, managing interictal schizophrenia demands comprehensive multidisciplinary collaboration between neurologists and psychiatrists. Atypical antipsychotics with lower seizure threshold risks represent the preferred choice for long-term stabilization. Regular therapeutic drug monitoring ensures optimal efficacy while minimizing neurotoxic drug interactions. Consequently, integrated neuropsychiatric care pathways substantially improve patient safety and long-term functional recovery.

Future Directions and Precision Medicine in Psychosis of Epilepsy

The integration of genomic diagnostics with advanced neuroimaging promises to transform the management of epilepsy-associated psychoses. As genetic testing becomes more accessible, early screening for rare pathogenic variants and polygenic burdens will guide individualized therapies. Furthermore, functional neuroimaging and cognitive profiling can delineate structural disruption across the default mode and cognitive control networks. In addition, novel targeted therapies modulating neuroinflammation, synaptic plasticity, and specific ionic channels may prevent psychotic decompensation in genetically vulnerable individuals. Clinical trials must continue investigating tailored pharmacotherapies that effectively control seizures without aggravating underlying psychiatric tendencies. Ultimately, establishing personalized precision medicine protocols will allow clinicians to address the dual burden of epilepsy and psychosis simultaneously, thereby improving long-term cognitive outcomes and overall quality of life for affected patients worldwide.

How does postictal psychosis differ clinically from interictal psychosis?

Postictal psychosis occurs shortly after a cluster of seizures, frequently following a brief lucid interval, and resolves within days or weeks. In contrast, interictal psychosis occurs independently of recent seizure frequency, presenting as a chronic or recurrent psychiatric illness that closely resembles primary schizophrenia without direct temporal coupling to seizures.

What genetic variants are most commonly associated with psychosis of epilepsy?

Patients with psychosis of epilepsy frequently harbor rare pathogenic variants in established epilepsy genes such as SCN1A, PCDH19, DEPDC5, KCNT1, CHD2, SLC2A1, NPRL3, and CACNA1A, along with chromosomal abnormalities. These rare high-penetrance mutations predominantly associate with chronic interictal schizophrenia-like phenotypes rather than acute postictal psychotic episodes.

How do schizophrenia polygenic risk scores influence phenotypes in epilepsy?

Schizophrenia polygenic risk scores are significantly elevated in patients who develop interictal schizophrenia, demonstrating a shared common genetic liability with primary psychiatric disease. However, polygenic risk scores are not elevated in patients with postictal psychosis, indicating that postictal episodes stem primarily from seizure-related network disruptions rather than common psychiatric genetics.

Disclaimer: This content is for informational and educational purposes only, and should not be taken as professional medical advice. Healthcare professionals should rely on their clinical judgment and refer to the latest local and national guidelines for clinical practice.

References

1. Rayner G et al. Psychoses of Epilepsy: Unravelling the Phenotypic and Genotypic Features. Ann Neurol. 2025 Jul. doi: 10.1002/ana.27209. PMID: 39950246.
2. Hilger E, et al. Psychoses in epilepsy: A comparison of postictal and interictal psychoses. Epilepsy Behav. 2016;60:58-62.
3. Allebone J, et al. Neuropsychological function in psychosis of epilepsy. Epilepsy Res. 2023;197:107222.
4. Chen Z, et al. Psychosis of Epilepsy: An Update on Clinical Classification and Mechanism. Brain Sci. 2025;15(1):35.